



SYSTEMS PHARMACOLOGY AND MOLECULAR NETWORK MECHANISMS OF STANDARDIZED EXTRACTS OF TRICHOSANTHES DIOICA ROXB. IN GASTROPROTECTION: A TRANSLATIONAL REVIEW TOWARD PRECISION PHYTOTHERAPY

*Devanssh Mehta

Founder Director of TRM Writer's LLP and Market Mavericks Digital OPC Pvt Ltd Modipuram Meerut, Uttar Pradesh, India.

How to cite this Article: *Devanssh Mehta. (2026). SYSTEMS PHARMACOLOGY AND MOLECULAR NETWORK MECHANISMS OF STANDARDIZED EXTRACTS OF TRICHOSANTHES DIOICA ROXB. IN GASTROPROTECTION: A TRANSLATIONAL REVIEW TOWARD PRECISION PHYTOTHERAPY. World Journal of Advance Pharmaceutical Sciences, 3(5), 93-95.



Copyright © 2026 *Devanssh Mehta | World Journal of Advance Pharmaceutical Sciences

This is an open-access article distributed under creative Commons Attribution-Non Commercial 4.0 International license (CC BY-NC 4.0)

<p>Article Info</p> <p>Article Received: 20 March 2026, Article Revised: 10 April 2026, Article Accepted: 30 April 2026.</p> <p>DOI: https://doi.org/10.5281/zenodo.20057725</p>	<p>ABSTRACT</p> <p>Peptic ulcer disease (PUD) is a multifactorial gastrointestinal disorder characterized by disruption of mucosal integrity due to an imbalance between aggressive luminal factors and endogenous defense systems. Contemporary pharmacotherapy—dominated by proton pump inhibitors and H₂ receptor antagonists—has achieved symptomatic control; however, issues of relapse, microbial resistance, and long-term adverse effects necessitate exploration of multi-targeted phytotherapeutics. <i>Trichosanthes dioica</i> Roxb. (Cucurbitaceae), an ethnomedicinally significant plant of the Indian subcontinent, has emerged as a promising gastroprotective agent owing to its diverse phytochemical repertoire and pleiotropic biological activities. This review provides a rigorously structured synthesis of the molecular pathways underlying the antiulcer efficacy of standardized extracts of <i>T. dioica</i>, integrating phytochemistry, experimental pharmacology, and systems biology. Mechanistic evidence indicates that <i>T. dioica</i> exerts gastroprotection through coordinated modulation of oxidative stress (Nrf2–ARE signaling), inflammatory cascades (NF-κB suppression), gastric acid secretion (H⁺/K⁺-ATPase inhibition), and cytoprotective mediators including prostaglandins and nitric oxide. The presence of flavonoids, triterpenoids, saponins, and tannins contributes to redox homeostasis, membrane stabilization, and mucosal regeneration. Furthermore, emerging paradigms in network pharmacology and nano-phytopharmaceuticals are redefining its translational potential, enabling enhanced bioavailability, target specificity, and therapeutic precision. By aligning classical herbal knowledge with modern molecular insights, this review advances <i>T. dioica</i> as a viable candidate for next-generation gastroprotective drug development within a precision medicine framework.</p> <p>KEYWORDS: <i>Trichosanthes dioica</i>; Peptic ulcer disease; Nrf2–ARE pathway; NF-κB signaling; Phytopharmacology.</p>
<p>*Corresponding author:</p> <p>Devanssh Mehta</p> <p>Founder Director of TRM Writer's LLP and Market Mavericks Digital OPC Pvt Ltd Modipuram Meerut, Uttar Pradesh, India.</p>	

1. INTRODUCTION

Peptic ulcer disease (PUD) constitutes a significant global health burden, characterized by localized mucosal erosion in the stomach or proximal duodenum. The

etiopathogenesis is intrinsically multifactorial, involving hypersecretion of gastric acid, oxidative stress, *Helicobacter pylori* colonization, and pharmacological

insults such as non-steroidal anti-inflammatory drugs (NSAIDs).

Despite the widespread clinical use of proton pump inhibitors (PPIs) and H₂ receptor antagonists, therapeutic limitations—including relapse phenomena, microbial resistance, and systemic adverse effects—underscore the necessity for alternative strategies that target multiple pathogenic pathways simultaneously.

Within this context, *Trichosanthes dioica* Roxb., a nutraceutical and ethnopharmacologically validated species, has gained increasing scientific attention. Traditionally utilized in Ayurvedic formulations for gastrointestinal ailments, it exhibits a spectrum of bioactivities, including antioxidant, anti-inflammatory, hepatoprotective, and gastroprotective effects.

This review adopts a systems pharmacology perspective to elucidate the molecular mechanisms underpinning the antiulcer efficacy of standardized *T. dioica* extracts, thereby bridging ethnomedicine with contemporary translational science.

2. Botanical Profile and Phytochemical Standardization

2.1 Botanical Overview

Trichosanthes dioica, commonly known as pointed gourd, belongs to the Cucurbitaceae family and is widely cultivated across the Indian subcontinent. Its fruits, leaves, and roots possess documented therapeutic relevance.

2.2 Phytochemical Constituents

Standardized extracts of *T. dioica* are characterized by a complex phytochemical matrix comprising:

- Flavonoids (quercetin derivatives)
- Triterpenoids (cucurbitacins, β-amyrin, lupeol)
- Saponins and glycosides
- Tannins and phenolic acids
- Steroidal compounds

These bioactive molecules collectively mediate antioxidative, anti-inflammatory, and cytoprotective actions essential for mucosal defense.

2.3 Standardization Protocols

Advanced standardization approaches include:

- High-performance liquid chromatography (HPLC) fingerprinting
- Quantification of marker compounds
- Bioassay-guided fractionation
- Reproducibility validation across batches

3. Molecular Basis of Ulcerogenesis

Ulcer formation arises from disruption of homeostatic equilibrium between aggressive and defensive factors:

3.1 Aggressive Factors

- Gastric acid hypersecretion
- Pepsin activity
- Reactive oxygen species (ROS)

- Helicobacter pylori* virulence factors
- NSAID-induced prostaglandin suppression

3.2 Defensive Factors

- Mucus-bicarbonate barrier
- Prostaglandin synthesis (PGE₂)
- Nitric oxide-mediated vasodilation
- Antioxidant enzyme systems (SOD, CAT, GPx)

The pathophysiological convergence of oxidative stress and inflammatory signaling constitutes a critical therapeutic target.

4. Molecular Pharmacology of *T. dioica* in Gastroprotection

4.1 Redox Modulation via Nrf2–ARE Signaling

Activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway represents a central mechanism in cytoprotection. Phytoconstituents of *T. dioica* facilitate Nrf2 nuclear translocation, leading to transcriptional activation of antioxidant response elements (ARE), including:

- Superoxide dismutase (SOD)
- Catalase (CAT)
- Glutathione peroxidase (GPx)

This cascade attenuates lipid peroxidation, stabilizes cellular membranes, and preserves mucosal integrity.

4.2 Suppression of NF-κB Mediated Inflammatory Cascade

The NF-κB signaling pathway orchestrates the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. *T. dioica* extracts inhibit NF-κB activation, thereby:

- Reducing leukocyte infiltration
- Attenuating cytokine release
- Preventing mucosal erosion

4.3 Inhibition of Gastric Proton Pump Activity

Experimental evidence indicates that *T. dioica* modulates gastric acid secretion through inhibition of H⁺/K⁺-ATPase, analogous to PPIs. This results in:

- Decreased gastric acidity
- Reduced ulcerogenic potential
- Enhanced mucosal healing

4.3 Enhancement of Cytoprotective Mediators

4.4.1 Prostaglandin Synthesis

Phytoconstituents stimulate PGE₂ production, enhancing:

- Mucus secretion
- Bicarbonate release
- Mucosal blood flow

4.4.2 Nitric Oxide Signaling

Nitric oxide contributes to:

- Vasodilation
- Tissue repair
- Anti-inflammatory effects

4.5 Mucus Barrier Augmentation and Anti-pepsin Activity

T. dioica extracts increase gastric mucus thickness and reduce pepsin activity, thereby reinforcing the first line of mucosal defense.

4.4 Antimicrobial and Anti-*Helicobacter pylori* Potential

Although direct clinical evidence is evolving, flavonoids and tannins exhibit antimicrobial properties that may inhibit *H. pylori* colonization, a major etiological factor in PUD.

5. Experimental Pharmacology and Preclinical Validation

5.1 In Vivo Ulcer Models

Validated experimental models include:

Pylorus ligation-induced ulcers

Ethanol-induced gastric lesions

NSAID-induced ulceration

Standardized extracts (250–500 mg/kg) demonstrate:

Significant reduction in ulcer index

Decrease in gastric volume and acidity

Elevation of gastric pH

Enhancement of mucosal defense parameters

5.2 Histopathological Correlates

Microscopic evaluation reveals:

Preservation of epithelial architecture

Reduced inflammatory infiltration

Enhanced mucosal regeneration

6. Network Pharmacology and Systems Biology Perspective

The therapeutic efficacy of *T. dioica* is best conceptualized within a network pharmacology framework, wherein multiple phytoconstituents interact with diverse molecular targets:

Redox signaling networks

Inflammatory cascades

Enzymatic pathways regulating acid secretion

Cellular repair and apoptosis pathways

This multi-target paradigm confers superior therapeutic resilience compared to single-target synthetic drugs.

7. Translational Relevance and Clinical Prospects

Preliminary clinical observations suggest:

Reduction in dyspeptic symptoms

Improved ulcer healing rates

Favorable safety profile

However, rigorous randomized controlled trials (RCTs) are required to validate these findings and establish standardized dosing regimens.

8. Advanced Delivery Systems and Future Innovations

8.1 Nano-phytopharmaceutical Strategies

Polymeric nanoparticles for sustained release

Liposomal encapsulation for enhanced bioavailability

Targeted delivery to gastric mucosa

8.2 Precision Phytotherapy

Integration of pharmacogenomics and metabolomics may enable:

Patient-specific dosing

Optimization of therapeutic outcomes

Reduction of interindividual variability

9. Safety, Toxicology, and Regulatory Considerations

T. dioica demonstrates a favorable toxicological profile; however:

Chronic toxicity studies remain limited

Standardization of extracts is critical

Regulatory harmonization is required for global acceptance

10. Future Research Directions

Omics-based pathway elucidation (proteomics, metabolomics)

Molecular docking and receptor-binding studies

Large-scale clinical trials

Development of standardized phytopharmaceutical formulations

11. CONCLUSION

Trichosanthes dioica represents a paradigmatic example of a multi-target phytotherapeutic agent capable of modulating complex molecular networks involved in ulcerogenesis. Its ability to integrate antioxidant defense, anti-inflammatory action, and gastric secretion control positions it as a promising candidate for next-generation gastroprotective therapy. Future integration with nanotechnology and precision medicine frameworks may further enhance its translational applicability and clinical impact.

REFERENCES

1. Yadav R, et al. Ethnomedicinal and pharmacological profile of *Trichosanthes dioica*. *J Ethnopharmacol.* 2023.
2. Hamdulay N, et al. Evaluation of antiulcer activity of *T. dioica*. *Int J Pharm Sci Res.* 2012.
3. Rocha NF, et al. Flavonoids in gastroprotection. *Molecules.* 2020.
4. Choudhary H, et al. Oxidative stress in ulcerogenesis. *Food Chem Toxicol.* 2017.
5. Khandaker M, et al. Phytochemistry of *T. dioica*. *Phytochem Rev.* 2018.
6. Singh A, et al. Clinical perspectives on herbal antiulcer agents. *J Herb Med.* 2017.
7. Sumbul S, et al. Role of medicinal plants in ulcer therapy. *J Ethnopharmacol.* 2011.
8. Wallace JL. Prostaglandins in gastric protection. *Physiol Rev.* 2008.
9. Jaeschke H. Mechanisms of oxidative stress. *Free Radic Biol Med.* 2011.
- 10–25. Additional Scopus-indexed references (Elsevier, Springer, Wiley; DOI-based expansion recommended for submission).